Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13250482 | 0.90 | APLNR (0.42) | APLNR | |
| SCHEMBL2080960 | 0.90 | APLNR (0.37) | APLNR | |
| SCHEMBL368782 | 0.83 | APLNR (0.36) | APLNR | |
| SCHEMBL20234629 | 0.81 | APLNR (0.34) | APLNR | |
| SCHEMBL26361642 | 0.81 | APLNR (0.31) | APLNR | |
| SCHEMBL3236600 | 0.81 | APLNR (0.31) | APLNR | |
| SCHEMBL3236611 | 0.81 | APLNR (0.31) | APLNR | |
| SCHEMBL337849 | 0.80 | APLNR (0.33) | APLNR | |
| SCHEMBL23350274 | 0.77 | MEN1 (0.31) | — | |
| SCHEMBL51112 | 0.75 | GPR119 (0.34) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-03 | — | — | US | disclosed |
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| US-20240058457-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4263552-A1 | BTK DEGRADER | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4225765-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3500556-B1 | PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140221380-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140221380-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | disclosed |
| US-8420666-B2 | Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-2124944-B1 | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors | RANBAXY LAB LTD (IN) | 2012-02-15 | — | — | EP | disclosed |
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| EP-2124944-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008111010-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292196-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE4A, PDE3A | APLNR 4384/4885 |
| US-20140221380-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | APLNR 4806/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | APLNR 1901/4885 |
| US-20240058457-A1 | BTK DEGRADER | BTK, LYN, SYK | APLNR 4420/4885 |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | APLNR 4839/4885 |
| US-20150175530-A1 | ANTIBACTERIAL AGENTS | MRPL21, ABCB11, LSS | APLNR 3364/4885 |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | APLNR 1901/4885 |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | APLNR 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.